“Gedatolisib plus Faslodex, with or without Ibrance, represents a potential new standard of care for patients with hormone ...

Research presented by Dr Erik Sahai has shown that early, reversible diversity in tumour cell state can blunt the effect of ...

Celcuity Inc. soared on best-in-class Phase 3 breast cancer data. Click to see why I have a Buy rating on CELC due to data, ...

In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

About Secura Bio, Inc. Secura Bio is an integrated, commercial-stage pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies for physicians ...

Secura Bio, Inc. ( an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today provided a corporate update, including an update on the encouraging enrollment ...

The clinical study is divided into two parts: a Phase I dose escalation stage and a Phase IIa dose expansion and optimisation stage.

Secura Bio, Inc. ( an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that duvelisib (COPIKTRA®) was added by the National Comprehensive Cancer ...

Expert Kelsey Martin shares nursing insights on balancing glucose control and GI side effects when caring for patients on PI3K and AKT inhibitors. Proactive monitoring of diarrhea and hyperglycemia, ...

An international research team has identified a previously unknown mechanism by which the breast cancer drug tamoxifen can increase the risk of secondary tumors in the uterus. The study shows that ...